[Effect of ritmilen and allapinin on prostanoid and cyclic nucleotide levels in patients with cardiac rhythm disorders].
The effect of antiarrhythmic drugs, ritmilen and allapinin, on endogenic prostanoid and cyclic nucleotide levels was examined in patients with heart rhythm disorders. Intravenous administration of antiarrhythmic agents is shown to be accompanied with increased release of prostacyclin that has antiarrhythmic properties into myocardial outflow. Both ritmilen and allapinin promoted the predominance of prostacyclin over thromboxane, with its intrinsic arrhythmogenic properties. Ritmilen- or allapinin-induced changes in prostaglandins E and F2 alpha consisted in that PGE prevailed, as compared to PGF2 alpha. There were no significant changes in cyclic nucleotide ratios (cAMP/cGMP) in response to treatment.
Smetnev
A S
AS
Bunin
Iu A
IuA
Smirnov
I E
IE
Asymbekova
E U
EU
Savchenko
A P
AP
D000157:Aconitine / Q000031:analogs & derivatives*; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000097:blood / Q000188:drug therapy*; D000242:Cyclic AMP / Q000097:blood; D006152:Cyclic GMP / Q000097:blood; D015237:Dinoprost; D004206:Disopyramide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009712:Nucleotides, Cyclic / Q000097:blood*; D011453:Prostaglandins / Q000097:blood*; D011458:Prostaglandins E / Q000097:blood; D011460:Prostaglandins F / Q000097:blood; D013268:Stimulation, Chemical
D000889:Anti-Arrhythmia Agents; D009712:Nucleotides, Cyclic; D011453:Prostaglandins; D011458:Prostaglandins E; D011460:Prostaglandins F; C051402:allapinin; D015237:Dinoprost; D000242:Cyclic AMP; D004206:Disopyramide; D006152:Cyclic GMP; D000157:Aconitine
Vliianie ritmilena i allapinina na soderzhanie prostanoidov i tsiklicheskikh nukleotidov u bol'nykh s narusheniiami ritma serdtsa.